Small cap biotech companies spend hundreds of millions of dollars and over ten years moving experimental drug candidates from concept to fully approved drugs. For late stage drug candidates, those in Phase III, positive or negative data can result in either massive gains or devastating declines in the sponsoring company's stock price. This "ultimate catalyst event" provides smart, organized & nimble option traders spectacular & consistent trading opportunities. In this unique book, the author provides individuals unfamiliar with the world of small cap biotech a fast, simplified and efficient approach to identify, analyze & execute trading strategies using options. The following topics, amongst others, are covered in this book: * Description of the FDA drug trial process, from pre-clinical to Phase III & beyond * Identification, categorization & organization of small cap biotech companies * Structured & streamlined approach to assess small cap biotech companies * Notes on trading strategy & tactics * Detailed description of option trading structures best suited for small cap biotech This book is an absolute "must have" for individuals thinking about trading in the fast paced and often confusing world of small cap biotech.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
T. Ayers Pelz was a trader on a major European bank's proprietary trading desk. He was responsible for a portfolio with limits of more than $200 million. Prior to proprietary trading, Mr. Pelz worked with several major investment banks in roles ranging from corporate finance, mergers and acquisitions to credit and business development. He has substantial international work experience in Asia, U.S., Europe and Latin America and was based in New York City, Bogotá (Colombia), Rio de Janeiro (Brazil) and Amsterdam (The Netherlands). Mr. Pelz currently resides in Denver, Colorado where he trades for his own account. He is married and has a young son.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
EUR 10,25 für den Versand von USA nach Deutschland
Versandziele, Kosten & DauerEUR 5,61 für den Versand von Vereinigtes Königreich nach Deutschland
Versandziele, Kosten & DauerAnbieter: -OnTimeBooks-, Phoenix, AZ, USA
Zustand: acceptable. Reading copy. May have signs of wear and previous use scuffs, library copy, highlighting, writing, and underlining . Dust jacket may be missing. 100% GUARANTEE! Shipped with delivery confirmation, if youâre not satisfied with purchase.Ships USPS Media Mail. Bestandsnummer des Verkäufers OTV.1450598536.A
Anzahl: 1 verfügbar
Anbieter: THE SAINT BOOKSTORE, Southport, Vereinigtes Königreich
Paperback / softback. Zustand: New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days 320. Bestandsnummer des Verkäufers C9781450598538
Anzahl: Mehr als 20 verfügbar
Anbieter: GreatBookPrices, Columbia, MD, USA
Zustand: New. Bestandsnummer des Verkäufers 9630756-n
Anzahl: Mehr als 20 verfügbar
Anbieter: GreatBookPrices, Columbia, MD, USA
Zustand: As New. Unread book in perfect condition. Bestandsnummer des Verkäufers 9630756
Anzahl: Mehr als 20 verfügbar
Anbieter: Best Price, Torrance, CA, USA
Zustand: New. SUPER FAST SHIPPING. Bestandsnummer des Verkäufers 9781450598538
Anzahl: 2 verfügbar
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
Zustand: New. Bestandsnummer des Verkäufers 9630756-n
Anzahl: Mehr als 20 verfügbar
Anbieter: CitiRetail, Stevenage, Vereinigtes Königreich
Paperback. Zustand: new. Paperback. Small cap biotech companies spend hundreds of millions of dollars and over ten years moving experimental drug candidates from concept to fully approved drugs. For late stage drug candidates, those in Phase III, positive or negative data can result in either massive gains or devastating declines in the sponsoring company's stock price. This "ultimate catalyst event" provides smart, organized & nimble option traders spectacular & consistent trading opportunities. In this unique book, the author provides individuals unfamiliar with the world of small cap biotech a fast, simplified and efficient approach to identify, analyze & execute trading strategies using options. The following topics, amongst others, are covered in this book: * Description of the FDA drug trial process, from pre-clinical to Phase III & beyond * Identification, categorization & organization of small cap biotech companies * Structured & streamlined approach to assess small cap biotech companies * Notes on trading strategy & tactics * Detailed description of option trading structures best suited for small cap biotech This book is an absolute "must have" for individuals thinking about trading in the fast paced and often confusing world of small cap biotech. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. Bestandsnummer des Verkäufers 9781450598538
Anzahl: 1 verfügbar
Anbieter: Sunshine State Books, Lithia, FL, USA
paperback. Zustand: As New. Paperback--no flaws. Bestandsnummer des Verkäufers SF250312009G223
Anzahl: 1 verfügbar
Anbieter: clickgoodwillbooks, Indianapolis, IN, USA
Zustand: acceptable. Used - Acceptable: All pages and the cover are intact, but shrink wrap, dust covers, or boxed set case may be missing. Pages may include limited notes, highlighting, or minor water damage but the text is readable. Item may be missing bundled media. Bestandsnummer des Verkäufers 3O6WBH000CLA_ns
Anzahl: 1 verfügbar
Anbieter: Treasure Island, Waltham, MA, USA
paperback. Zustand: New. Bestandsnummer des Verkäufers 53HN5000011O
Anzahl: 1 verfügbar